We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Kensey Nash Corp. (MM) | NASDAQ:KNSY | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 38.45 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE TO
(Amendment No. 1)
TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)
OF THE SECURITIES EXCHANGE ACT OF 1934
KENSEY NASH CORPORATION
(Name of Subject Company (Issuer))
KONINKLIJKE DSM N.V.
BIOMEDICAL ACQUISITION CORPORATION
(Name of Filing Persons (Offerors))
Common Stock, $0.001 Par Value Per Share
(Title of Class of Securities)
490057106
(CUSIP Number of Class of Securities)
Hugh C. Welsh
President
DSM North America
45 Waterview Boulevard
Parsippany, NJ 07054
(973) 257-8300
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications on Behalf of Filing Persons)
Copies to:
William A. Groll
Cleary Gottlieb Steen & Hamilton LLP
One Liberty Plaza
New York, New York 10006
(212) 225-2000
CALCULATION OF FILING FEE
Transaction Valuation*
|
Amount of Filing Fee**
|
|
---|---|---|
$401,874,049.50 | $46,054.77 | |
Amount Previously Paid: | $46,054.77 | Filing Party: | Koninklijke DSM N.V., Biomedical Acquisition Corporation | ||||
Form or Registration No.: | Schedule TO | Date Filed: | May 21, 2012 |
Check the appropriate boxes below to designate any transactions to which the statement relates:
Check the following box if the filing is a final amendment reporting the results of the tender offer: o
This Amendment No. 1 (this " Amendment ") amends and supplements the Tender Offer Statement on Schedule TO (as amended, the " Schedule TO ") originally filed on May 21, 2012 in connection with the offer by Biomedical Acquisition Corporation, a Delaware corporation (" Purchaser ") and an indirect wholly-owned subsidiary of Koninklijke DSM N.V., a corporation organized in the Netherlands (" DSM "), to purchase all outstanding shares of common stock, par value $0.001, including the associated Series A Junior Participating Preferred Stock Purchase Rights (the " Shares "), of Kensey Nash Corporation, a Delaware corporation (" Kensey Nash "), at a price of $38.50 per Share, net to the seller in cash, without interest thereon and less any required withholding taxes, upon the terms and subject to the conditions set forth in the Offer to Purchase dated May 21, 2012 (the " Offer to Purchase "), which is annexed to and filed with the Schedule TO as Exhibit (a)(1)(A), and in the related Letter of Transmittal, which is annexed to and filed with the Schedule TO as Exhibit (a)(1)(B), which, together with any amendments or supplements thereto, collectively constitute the " Offer ."
All capitalized terms used in this Amendment without definition have the meanings ascribed to them in the Schedule TO.
Item 11.
Additional Information.
Item 11 is hereby amended and supplemented by adding the following paragraph to Section 15"Certain Legal MattersAntitrust Compliance" of the Offer to Purchase:
On June 6, 2012, DSM issued a press release, the full text of which is filed as Exhibit (a)(5)(H) to this Amendment and is incorporated by reference herein, announcing the expiration of the mandatory waiting period under the HSR Act with respect to the Offer. This condition of the Offer is thus satisfied.
Item 11 is hereby amended and supplemented by adding the following paragraph to Section 15"Certain Legal MattersLitigation" of the Offer to Purchase:
On May 25, 2012, an amended complaint was filed by the plaintiff in the action captioned Hilary Coyne v. Kensey Nash Corporation, et. al. (Case No. 7508) (the " Amended Complaint "). In addition to the allegations previously made in the original complaint, as described in this Offer to Purchase, the amended complaint generally alleges that Kensey Nash's Recommendation Statement on Schedule 14D-9 is materially misleading and incomplete. Kensey Nash has stated that it continues to believe the lawsuit is without merit. On May 29, 2012, all three of the plaintiffs in the previously filed lawsuits moved to have their cases consolidated, and to have the Amended Complaint serve as the operative complaint for the consolidated proceedings. On June 4, 2012, the Court of Chancery granted that motion.
On May 29, 2012, the plaintiffs also filed motions (i) for expedited proceedings and (ii) for a preliminary injunction. On June 4, 2012, the Court of Chancery heard argument on the motion for expedited proceedings and on June 5, 2012, denied that motion. Kensey Nash and DSM intend to contest the motion for a preliminary injunction if plaintiffs continue to pursue that motion.
(a)(5)(H) | Press Release issued by DSM on June 6, 2012 |
2
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated:
June 6, 2012
KONINKLIJKE DSM N.V. | ||||||
|
|
By: |
|
/s/ Hugh C. Welsh Name: Hugh C. Welsh Title: President and General Counsel, DSM North America |
|
|
|
|
|
|
|
|
|
BIOMEDICAL ACQUISITION CORPORATION | ||||||
|
|
By: |
|
/s/ Hugh C. Welsh Name: Hugh C. Welsh Title: Secretary and Director |
|
|
3
(a)(5)(H) | Press Release issued by DSM on June 6, 2012 |
4
1 Year Kensey Nash Chart |
1 Month Kensey Nash Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions